Anti-CD40 Therapy in Sjögren's Disease

jjcush@gmail.com
Aug 13, 2024 12:01 pm
Sjögren's disease is a chronic autoimmune condition without a clear effective therapy - DMARD or biologic. The TWINSS study has demonstrated the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in a phase 2 randomized clinical trial of active Sjögren's disease (SD).
 
This randomised, double-blind, placebo-controlled study enrolled adults with SD meeting the 2026 ACR/EULAR 2016 criteria. The study enrolled 2 cohorts: 
  • Cohort 1: dose-ranging study of SD patients with a EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score of 5 or higher and a EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score of 5 or higher. Patients received either subcutaneous iscalimab 150 mg, 300 mg, 600 mg, or placebo.
  • Cohort 2: patients with an ESSDAI score of less than 5, ESSPRI (dryness or fatigue) score of 5 or higher, and Impact of Dry Eye on Everyday Life score of 30 or higher were randomly assigned to iscalimab 600 mg or placebo. 
  • The primary objectives were to demonstrate a dose–response relationship of iscalimab based on the change in ESSDAI from baseline to week 24 in cohort 1 and the effect of iscalimab 600 mg on ESSPRI at week 24 in cohort 2.
 
A total of 173 patients were treated in cohort 1 (44 to iscalimab 150 mg, 43 to 300 mg, 43 to 600 mg, and 43 to placebo) and 100 in cohort 2 (50 to each group). 
 
Cohort 1 results: 
  • a significant dose–response relationship was shown
  • At week 24, ESSDAI decreased all three doses of iscalimab; 150 mg and 600 mg doses 
Cohort 2 results: 
  • ESSPRI trended towards improvement with iscalimab 600 mg (but was non-significant; p=0·12)
Serious adverse events were reported in nine patients in cohort 1 and four patients in cohort 2. There were no deaths.
 
The anti-CD40 mAb Iscalimab, was well tolerated and showed evidence of clinical benefit in this early phase 2 trial. Larger trials are needed to confirm efficacy and safety. 
Continue Reading
Steroid Use Biologic Use Referrals to Rheums Comanagement w/ PCPs

More ACR Coverage:

Back to ACR Coverage

Back to Novel Rx Coverage at ACR

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures

Disclosures
The author has no conflicts of interest to disclose related to this subject
×